Although there are meta-analyses on the effect of SGLT2 inhibitors on cardiometabolic markers after myocardial infarction, there is a lack of data on the impact of SGLT2 inhibitors on clinical and functional cardiac remodeling outcomes in patients with AMI[20–22]. This evidence concerns the gene SLC5A2 and myocardial infarction.